HENLIUS(02696) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.
Yahoo FinanceApr 23 06:00 ET
Fosun International Unit to Boost Stake in Henlius Biotech
MT NewswiresApr 22 10:52 ET
Hong Kong stocks movement | HENLIUS (02696) rises again by over 9% as FOSUN PHARMA plans to increase its shareholding of HENLIUS by 3.87% for 0.517 billion HKD.
HENLIUS (02696) rose more than 9% again, as of the time of writing, it increased by 8.54%, reaching 36.85 Hong Kong dollars, with a transaction amount of 35.2823 million Hong Kong dollars.
Zhitong FinanceApr 21 22:32 ET
After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.
① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.
cls.cnApr 21 08:21 ET
FOSUN INTL (00656) increased its Shareholding in HENLIUS (02696) by a total of 3.87%.
FOSUN INTL (00656) announced that on April 17, 2025, FOSUN PHARMA industry (the company through FOSUN...
Zhitong FinanceApr 21 06:21 ET
Express News | Discloseable Transaction in Relation to Acquisition of Henlius
ReutersApr 21 06:06 ET

Comments

Spinee

Jun 25, 2024 10:45

HSI Opens Up 60 pts; LI AUTO & NIO Advance, as HENLIUS Rockets 21%

Hong Kong stocks opened higher in the morning. $Hang Seng Index (800000.HK)$opened 60 points or 0.3% higher at 18,088. $Hang Seng China Enterprises Index (800100.HK)$ opened 22 points or 0.3% higher at 6,463. $Hang Seng TECH Index (800700.HK)$ opened 11 points or 0.3% higher at 3,689.
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...

1

Moomoo AI

Jan 25, 2024 06:24

Investors' belief in the company's poor revenue performance is likely causing its low P/S ratio. The company's bleak revenue outlook is contributing to its low P/S. These conditions form a barrier for the share price at these levels.

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Moomoo AI

Nov 22, 2023 10:17

Shanghai Henlius Biotech's statutory profit might not fully reflect the company's underlying earning capacity due to unusual item expense. The change from loss to profit is a positive turn for the firm.